• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by TradeUP Acquisition Corp.

    10/5/23 1:14:05 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $UPTD alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 333-253322
    Issuer: Estrella Immunopharma, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 437 Madison Avenue, 27th Floor
    New York NEW YORK 10022
    Telephone number: (732) 910-9692
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    TradeUP Acquisition Corp. Unit
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-10-05 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $UPTD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPTD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPTD
    SEC Filings

    View All

    SEC Form 10-Q filed by TradeUP Acquisition Corp.

    10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)

    2/14/24 5:28:53 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by TradeUP Acquisition Corp.

    424B3 - Estrella Immunopharma, Inc. (0001844417) (Filer)

    2/12/24 5:02:06 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TradeUP Acquisition Corp. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)

    2/2/24 8:30:07 AM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $UPTD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

    Estrella to Begin Trading on NASDAQ Under the Ticker Symbols "ESLA" and "ESLAW" Beginning October 2, 2023 NEW YORK, Sept. 29, 2023 /PRNewswire/ -- Estrella Immunopharma, Inc., formerly known as TradeUP Acquisition Corp. ("UPTD") (NASDAQ:UPTD, UPTDW, UPTDU))), today announced the successful closing of its business combination with Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.  The resulting combined company will operate under the name Estrella Immunopharma, Inc. and will be led by Estrella Founder and CEO Dr. Cheng Liu. The com

    9/29/23 10:34:00 AM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

    NEW YORK, Sept. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ:UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination from September 19, 2023 to October 19, 2023, for each public share that is not redeemed by the Company's stockholders in connection with such extension (collectively, the "Remaining Shares", each, a "Remaining Share"), the Company has deposited into its trust account (the "Trust Account") an aggregate of $37,432.70 (the "Monthly Extension Fee"), representing $0.05 per Remaining Share of the Company. The payment for such Monthly Extension Fee was made by Estrella Biop

    9/18/23 5:00:00 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

    NEW YORK, Aug. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ:UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination from August 19, 2023 to September 19, 2023, for each public share that is not redeemed by the Company's stockholders in connection with such extension (collectively, the "Remaining Shares", each, a "Remaining Share"), the Company has deposited into its trust account (the "Trust Account") an aggregate of $37,432.70 (the "Monthly Extension Fee"), representing $0.05 per Remaining Share of the Company. The payment for such Monthly Extension Fee was made by Estrella Biophar

    8/18/23 4:30:00 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $UPTD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Xu Jiandong claimed ownership of 264,388 shares (SEC Form 3)

    3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

    10/10/23 4:18:19 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Roberts Marsha

    3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

    10/10/23 4:17:50 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Xu Pei

    3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

    10/10/23 4:17:25 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $UPTD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by TradeUP Acquisition Corp.

    SC 13D - Estrella Immunopharma, Inc. (0001844417) (Subject)

    10/27/23 7:27:00 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by TradeUP Acquisition Corp. (Amendment)

    SC 13G/A - TradeUP Acquisition Corp. (0001844417) (Subject)

    3/10/23 4:04:07 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by TradeUP Acquisition Corp. (Amendment)

    SC 13G/A - TradeUP Acquisition Corp. (0001844417) (Subject)

    2/14/23 4:49:44 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care